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Aims Dysregulation of the bone morphogenetic protein receptor type 2 (BMPR2) is a hallmark feature that has been
described in several forms of pulmonary hypertension. We recently identified the microRNA miR-20a within a
highly conserved pathway as a regulator of the expression of BMPR2. To address the pathophysiological relevance
of this pathway in vivo, we employed antagomiR-20a and investigated whether specific inhibition of miR-20a could
restore functional levels of BMPR2 and, in turn, might prevent pulmonary arterial vascular remodelling.
Methods
and results
For specific inhibition of miR-20a, cholesterol-modified RNA oligonucleotides (antagomiR-20a) were synthesized.
The experiments in mice were performed by using the hypoxia-induced mouse model for pulmonary hypertension
and animal tissues were analysed for right ventricular hypertrophy and pulmonary arterial vascular remodelling.
Treatment with antagomiR-20a enhanced the expression levels of BMPR2 in lung tissues; moreover, antagomiR-
20a significantly reduced wall thickness and luminal occlusion of small pulmonary arteries and reduced right ventricu-
lar hypertrophy. To assess BMPR2 signalling and proliferation, we performed in vitro experiments with human
pulmonary arterial smooth muscle cells (HPASMCs). Transfection of HPASMCs with antagomiR-20a resulted in
activation of downstream targets of BMPR2 showing increased activation of Id-1 and Id-2. Proliferation of
HPASMCs was found to be reduced upon transfection with antagomiR-20a.
Conclusion This is the first report showing that miR-20a can be specifically targeted in an in vivo model for pulmonary hyperten-
sion. Our data emphasize that treatment with antagomiR-20a restores functional levels of BMPR2 in pulmonary
arteries and prevents the development of vascular remodelling.
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Introduction
Vascular remodelling of small pulmonary arteries is, together with
vasoconstriction and microthrombosis, one of the pathogenetic
hallmarks of pulmonary arterial hypertension (PAH). However, it
is largely unknown what causes vascular remodelling or how it
can be treated. Genetic mutations of the bone morphogenetic
protein receptor type II (BMPR2), a member of the transforming
growth factor (TGF-) b family expressed on the surface of endo-
thelial and vascular smooth muscle cells of the pulmonary arterial
circulation, have been described in familial and idiopathic PAH.1,2
Moreover, reduced expression of BMPR2 without concomitant
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mutations has also been found in other forms of pulmonary hyper-
tension including established animal models of the disease.3–5 It
has been debated controversially whether the altered expression
of BMPR2 due to mutations or down-regulation might have a func-
tional readout and, thus, an impact on the pathogenesis of PAH.
Two recent studies, however, have underscored the potential
role of BMPR2-mediated signalling for vascular remodelling.6,7
Long et al.6 observed that dysfunctional BMPR2/TGF-b signal
transduction results in altered expression of transcription factors,
including Smads and Id (inhibitor of DNA binding), leading to
migration of vascular smooth muscle cells. Similar findings have
been reported by another study showing that heterogeneous
mutations of BMPR2 are associated with disrupted Smad signalling
resulting in a pro-proliferative and anti-apoptotic phenotype of pul-
monary arterial smooth muscle cells.7
MicroRNAs (miRNAs) comprise a class of small, non-coding
RNA molecules that regulate gene expression on the post-
transcriptional level;8 miRNAs preferentially bind to conserved
regions in the 3′ untranslated region (UTR) of their target genes
and either suppress the translation or the mRNA stability of
these genes.9 There is a growing body of evidence that the abnor-
mal expression of miRNAs modulates human diseases by regulat-
ing key molecules of apoptosis, proliferation, or cell signalling.10
Conversely, efficient and non-toxic inhibition of miRNAs in vivo
is of particular interest since such methods would offer a thera-
peutic approach to suppress altered miRNA expression in
human disease. Krutzfeldt et al.11 recently described the inhibition
of miRNAs by the application of small anti-sense RNA molecules
conjugated with cholesterol called antagomiRs in mice.
We have recently proposed that miRNAs might regulate the
expression of BMPR2 and identified a phylogenetically conserved
pathway involving the action of the signal transducer and activator
of transcription (STAT)3 and the microRNA cluster miR-17/92,
mainly of miR-20a.12 Others have emphasized this hypothesis by
showing that miRNAs derived from miR-17/92 are overexpressed
in experimental pulmonary hypertension in vivo13 making these
miRNAs interesting targets for further investigations. With
respect to pathogenesis and therapy, this model offers the poten-
tial to restore functional expression levels of BMPR2 by antagoniz-
ing distinct miRNAs.
In the present study, we addressed feasibility and functional
readout of specific antagonization of miR20-a by using antagomiR
in an animal model of hypoxia-induced pulmonary hypertension
in vivo and in vitro.
Methods
Animal experiments
Male mice (BL6) were obtained by the Institute for Veterinary Physi-
ology at the University of Zurich. The study design of the in vivo experi-
ments is provided in Figure 1A. Four animal groups were used (n ¼ 8
each): three groups were employed in hypoxic conditions. The fraction
of oxygen was decreased gradually from 21 to 10% over 60 min.
Hypoxic conditions were provided by chambers connected to a gas
mixer (Ruskinn Life Science). Animals were treated with
antagomiR-20a (25 mg/kg), antagomiR negative control (antago-
miR_MM), or phosphate buffered saline (PBS), respectively. Injections
were performed at baseline (Day 0) with boosters at Day 5 and 12.
Blood analysis, morphometry, and tissue preparation for later analysis
were performed on Day 21. The experiments were approved by
Zurich Canton’s Veterinary office. To assess morphometry, hearts
and lungs were removed, formalin-fixed without prior perfusion,
paraffin-embedded and stained with haematoxylin and eosin. Heart
hypertrophy, cell wall thickness, and vessel occlusion were determined
by using the MCID analysis program 7.0 (InterFocus Imaging, Cam-
bridge, UK).
AntagomiR design
Cholesterol-modified RNA oligonucleotides (antagomiRs) directed
against human and murine miR-20a (MIMAT0000529) were designed
as described11 and synthesized by Microsynth (Microsynth, Balgach,
Switzerland). As a negative control, twelve point mutations were intro-
duced into the miR-20a mature sequence (antagomiR_MM) creating an
RNA sequence that is not encoded in the murine or human genome.
Statistics
For statistical analysis, GraphPad Prism Software (GraphPad Software,
San Diego, CA, USA) was used. To compare samples with parametric
distribution, the paired or unpaired t-test was applied and a P-value
,0.05 was considered to be statistically significant (*P, 0.05, **P,
0.01, ***P, 0.001). For statistical analysis between more than two
groups one-way ANOVA (Tukey post-test) was used. In all statistical
analyses, two-sided tests were applied. A table showing all statistical
analyses is provided (Supplementary material online, Table S1). All
data are shown as mean+ SD.
Extensive materials and methods are provided in the Supplementary
material online.
Results
Application of antagomiR-20a suppresses
miR-20a expression in target tissues
We recently identified a novel signalling pathway that regulates the
expression of BMPR2 through the action of miR-20a.12 Here, we
addressed the implications of this pathway in an animal model of
hypoxia-induced pulmonary hypertension. The in vivo experiments
were performed as described in the section ‘Methods’ (Figure 1A).
As shown in Figure 1B, repeated i.p. injections of antagomiR-20a
significantly down-regulated the expression levels of miR-20a in
lung tissues when assessed by qPCR at Day 21. AntagomiR-
20a-treated animals showed an expression level of miR-20a of
DCt 3.68+0.58 when compared with DCt 2.31+ 0.23 in nor-
moxic control animals thus resulting in a reduction in 59.3%
(P, 0.001). On the other hand, no significant changes were
observed between normoxic control mice and antagomiR_
mismatch (antagomiR_MM, DCt 2.46+0.2) or PBS (DCt 2.18+
0.26) treated animals. Similar results were observed for other
tissues analysed, in the particular heart and liver (data not
shown). These data indicate that intraperitoneally injected antago-
miRs are not subjected to a significant hepatic first-pass effect and,
thus, are a feasible approach to inhibit the expression of distinct
miRNAs in target tissues including the lungs. The sequences of
antagomiR-20a and antagomiR_MM are provided in Figure 1C.
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AntagomiR-20a prevents the
development of hypoxia-induced
morphological changes within the
cardiopulmonary circulation
Morphometric analyses were performed to assess the functional
and haemodynamic consequences of reduced expression levels
of miR-20a achieved by the application of antagomiR-20a. Repre-
sentative images of pulmonary arterioles stained for a-smooth
muscle actin are shown in Figure 2A; treatment with antagomiR-20a
significantly inhibited the vascular remodelling observed in PBS-
and antagomiR_MM-treated hypoxic animals. Computer-based
analysis further quantified the occlusion of these vessels to be
reduced from 13.47+0.73 and 13.33+0.61 (antagomiR_MM-
and PBS-treated animals, respectively) to 7.72+0.93 in
antagomiR-20a-treated mice or to 1.73+ 0.48 in normoxic con-
trols (Figure 2B). Similar effects were observed for the thickness
of the vessel wall showing a reduction from 1.18+0.06 and
1.28+0.15 mM in antagomiR_MM- and PBS-treated animals to
0.96+0.05 mM in antagomiR-20a-treated animals (0.71+
0.04 mM in normoxic controls; Figure 2C).
Right ventricular hypertrophy, assessed in Figure 2D, after 10%
O2 for 21 days was strongly reduced in animals receiving
antagomiR- when compared with hypoxic mice treated with antag-
omiR_MM or PBS (representative images are shown in Figure 2D).
These results were confirmed by calculating heart weight relative
to body weight (antagomiR_MM: 0.0061+0.0006 vs.
antagomiR-20a: 0.0056+ 0.0007; Figure 2E) and by the relation
of the right ventricular to the left ventricular volume (RV/LV +
S; antagomiR_MM: 0.25+0.01; antagomiR-20a: 0.21+0.01;
Figure 2F), indicating that the right ventricular afterload was
reduced in antagomiR-20a-treated mice when compared with
mock-treated hypoxic animals. Blood analysis performed at Day
21 revealed that hypoxia resulted in erythrocytosis, which was
most prominent in hypoxic PBS-treated animals (Figure 2G).
Whereas significant differences were observed between normoxic
controls (11.63+0.91 g/dL) and all hypoxic groups (20.23+
2.04 g/dL for antagomiR-20a, 21.75+1.28 g/dL for antago-
miR_MM, and 23.27+1.31 g/dL for PBS, respectively), differences
between antagomiR-20a- and antagomiR_MM-treated animals did
not reach statistical significance.
These data imply that the pathomorphological sequelae of
hypoxia on the pulmonary vasculature, which lead to the develop-
ment of pulmonary hypertension and, subsequently, to right ven-
tricular hypertrophy, can be prevented by the application of
antagomiR-20a.
Figure 1 AntagomiR-20a suppresses miR-20a expression in vivo. (A) Study design of the in vivo experiments. Four groups of eight animals each
were used; three groups were employed in conditions at 10% oxygen for up to 21 days and were treated with antagomiR-20a (25 mg/kg),
antagomiR_MM or PBS. Injections were performed at Day 0, 5, and 12. One group was used as a normoxic control. (B) miR-20a expression
as normalized to snoRNA202 is significantly down-regulated upon treatment with antagomiR-20a in lung tissue. (C) Sequence of antagomiR-20a
and of the mismatch control, antagomiR_MM.
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Figure 2 AntagomiR-20a prevents pulmonary arterial vascular remodelling. (A) Representative images of small pulmonary arteries stained
against a-smooth muscle actin showing reduced hypoxia-induced remodelling of intimal and medial vessel layer upon treatment with
antagomiR-20a (second from left), quantified by the analysis of lung vessel occlusion (B) and thickness of the vessel wall (C). Similar findings
were observed for heart morphometry as shown by representative images revealing reduced right ventricular hypertrophy by treatment
with antagomiR-20a (D, second from left), heart weight relative to body weight (E) and heart hypertrophy (F ). Hypoxia-induced erythrocytosis
was not affected significantly by treatment with antagomiR-20a (G).
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AntagomiR-20a restores functional
expression levels of bone morphogenetic
protein receptor type 2 in mice
Since we hypothesized that the reduced expression levels of
BMPR2 observed in pulmonary hypertension might be due to tar-
geted inhibition by miR-20a,12 we next investigated whether the
application of specific antagomiRs to mice increases BMPR2
expression levels, and whether restoration of this receptor might
have functional implications. As shown in Figure 3A, the mRNA
expression levels of BMPR2 in lung tissue were found to be
reduced in both hypoxic control groups (antagomiR_MM: DCt
3.36+0.73; PBS: DCt 3.2+ 0.41) when compared with normoxic
mice (DCt 2.61+ 0.19). Interestingly, mRNA levels of BMPR2
under hypoxic conditions could be normalized to the levels
observed in normoxic control animals by the application of
antagomiR-20a (DCt 2.68+0.16, Figure 3A). These findings are
further illustrated by immunohistochemical and western blot
analysis using antibodies directed against BMPR2 showing that
the application of antagomiR-20a increased the expression of
BMPR2 on endothelial and smooth muscle cells of pulmonary
arterioles when compared with antagomiR_MM-injected mice
(Figure 3B) and PBS-treated hypoxic mice (Figure 3C, western
blots provided as Supplementary material online, Figure S1).
Similarly, Smad5 and Id-2, two validated signalling elements
downstream of the BMPR2 pathway14 showed enhanced expres-
sion levels in lung tissues of animals treated with antagomiR-20a
when compared with hypoxic controls (Smad5: antagomiR-20a
DCt 3.89+0.2 vs. hypoxia PBS DCt 4.16+0.26, Figure 3D; Id-2:
antagomiR-20a DCt 5.09+0.46 vs. hypoxia PBS DCt 5.68+
0.52, Figure 3E). Expression levels for Id-1, however, were not
found to be changed in normoxic or hypoxic animals (Supplemen-
tary material online, Figure S2). Protein analysis by western blotting
for Id-2 further confirmed these findings and is provided as supple-
mentary information (Supplementary material online, Figure S3).
These data suggest that treatment with antagomiR-20a increases
expression levels of BMPR2 within the pulmonary vasculature
and, most important, restored functional BMPR2 signalling.
AntagomiR-20a enhances
BMP-2-mediated signalling in vitro
Upon binding of the ligand BMP-2 to BMPR2, Smad5 is activated by
phosphorylation, which, in turn, induces the expression of the
Figure 3 Restoration of functional expression levels of bone morphogenetic protein receptor type 2 by antagomiR-20a in mice. Treatment
with antagomiR-20a increased the expression of bone morphogenetic protein receptor type 2 in lung tissue as shown by qPCR (A), immuno-
histochemistry (B) (antagomiR-20a-treated animals shown in upper panel, antagomiR_MM in lower panel, magnification 200-fold), and (C )
western blotting. Similarly, expression of Smad 5 (D) and Id-2 (E) was increased in lung tissue by treatment with antagomiR-20a.
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transcription factors Id-1 and -2. Since treatment with
antagomiR-20a up-regulated the expression levels of BMPR2 in
vivo, we next investigated whether antagonization of miR-20a
might also enhance the BMP-2-mediated signalling in vitro. We
thus utilized human pulmonary arterial smooth muscle cells
(HPASMCs) that were stimulated with BMP-2 for different time
periods and found that treatment with antagomiR-20a enhanced
BMPR2-induced signalling activity, i.e. the expression levels of
Id-1 and -2 showed an augmentation of the BMP-2-mediated in-
duction of gene expression by transfection of antagomiR-20a. As
shown in Figure 4A, 1 h of BMP-2 stimulation enhanced the
mRNA levels of Id-1 in antagomiR-20a-treated cells by 2.65+
1.55-fold (when compared with 1.52+0.5-fold in
antagomiR_MM-transfected cells, P ¼ 0.102). After 4 h of BMP-2
stimulation Id-1 was significantly more induced in HPASMCs
treated with antagomiR-20a (4+2.28) when compared with
control cells (3+ 2.14, P ¼ 0.035). The mRNA levels of Id-2, on
the other hand, were found to be significantly more elevated by
BMP-2 stimulation in antagomiR-20a-treated HPASMCs after 1 h
only (antagomiR_MM: 1.14+0.31-fold, antagomiR-20a: 1.65+
0.41-fold, P ¼ 0.02, Figure 4B).
Finally, promoter studies were performed to illustrate an en-
hancement of BMP-2 signalling by antagonizing miR-20a. The pro-
moter of Id-1 containing multiple Smad transcription factor binding
sites15 was cloned into a luciferase-based reporter gene vector. As
shown in Figure 4D, 4 h of BMP-2 stimulation induced the relative
promoter activity of Id-1 by 1.38+ 0.22-fold in antagomiR_MM
transfected cells. Interestingly, the increase in promoter activity
upon stimulation with BMP-2 was significantly more enhanced
when cells were transfected with antagomiR-20a (1.69+
0.22-fold, P ¼ 0.016). Conversely, the overexpression of miR-20a
by transfection of small RNA oligonucleotides (mat-miR-20a)
reduced the BMP-2-mediated induction of the promoter activity
of Id-1 (mat-miR_MM: 1.81+ 0.27-fold; mat-miR-20a: 1.47+
0.35-fold, P ¼ 0.013; Figure 4E).
Note that, Smad5 was predicted to be directly targeted by
miR-20a (TargetScan, Whitehead Institute for Biomedical Research,
www.targetscan.org,16). Accordingly, the expression of Smad5 after
silencing of miR-20a in HPASMCswas analysed. As shown in Supple-
mentary material online, Figure S4, transfection of antagomiR-20a
significantly increased mRNA levels of Smad5 after 72 h, but failed
to enhance protein levels. Moreover, a reporter gene assay com-
prising the predicted seed match of miR-20a in the 3′ UTR of
Smad5 could not show a direct miRNA–mRNA interaction. Phos-
phorylation of Smad5 (normalized to Smad5 protein levels),
however, showed a trend towards enhanced phosphorylation
activity in stimulated as well as in unstimulated conditions when
compared with antagomiR_MM controls, but these data did
not reach statistical significance (Supplementary material online,
Figure S5).
Figure 4 AntagomiR-20a enhances BMP-2 mediated signalling in vitro. Expression of Id-1 (A) and Id-2 (B) is significantly increased after stimu-
lation with BMP-2 when transfected with antagomiR-20a (assessed at 1 and 4 h). Dashed line indicates unstimulated human pulmonary arterial
smooth muscle cells. (C) For promoter studies, the promoter of human Id-1 was cloned containing multiple Smad transcription factor binding
sites (as described in Lopez-Rovira et al.15). (D) The reporter gene assay in HepG2 cells: co-transfection of pGL3basic-Id-1 and antagomiR_MM
or antagomiR-20a. Stimulation with BMP-2 for 4 h increased response in antagomiR-20a-treated cells. (E) Conversely, the response to BMP-2
was reduced when miR-20a was overexpressed.
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Proliferation of vascular smooth muscle
cells is reduced upon transfection with
antagomiR-20a
Proliferation of pulmonary arterial smooth muscle cells is an
essential part of the vascular remodelling in pulmonary hyperten-
sion; we thus addressed whether transfection with antagomiR-20a
affects proliferation assessed by the BrdU assay. As shown in
Figure 5A, proliferation was significantly reduced in antagomiR-20a-
transfected HPASMCs (A450nm: from 1.229+ 0.182 to 0.867+
0.3) resulting in a reduction by 29.5% when compared with
antagomiR_MM-transfected controls (P ¼ 0.018); conversely,
when cells were transfected with precursor molecules of
miR-20a (pre-miR-20a), proliferation was significantly increased
(A450nm: from 1.049+0.223 to 1.576+ 0.418, or by 50.2%, re-
spectively. P ¼ 0.012). On the other hand, no significant changes
were seen when apoptosis was analysed (Supplementary material
online, Figure S6). AntagomiR-20a transfection of HPASMCs
resulted after 24 h in up-regulation of the cell cycle inhibitor
p21 on the protein level (antagomiR_MM: 0.232+0.112 vs.
antagomiR-20a: 0.804+ 0.077, P, 0.001 Figure 5B) as well as on
the mRNA level (1.53+ 0.43-fold, P ¼ 0.051 Figure 5C). The ex-
pression of miR-20a was analysed in the same samples showing
down-regulation of miR-20a in HPASMCs by antagomiR-20a treat-
ment (Figure 5D).
Discussion
We have recently identified a microRNA-mediated signalling
pathway that regulates the expression of BMPR2 on human pul-
monary arterial endothelial cells.12 While this pathway might
explain, at least in vitro, the reduced expression of BMPR2 as
observed in several forms of pulmonary hypertension, the func-
tional relevance of this pathway was unclear so far. A very
recent study has confirmed the pathogenetic importance of the
microRNA cluster 17/92 by inhibition of miR-17 in experimental
pulmonary hypertension;17 based on our previous work that iden-
tified two functionally related miRs as regulators of BMPR2 expres-
sion, i.e. miR-17 and miR-20a but the latter one being more
potent,12 we focused here on the action of miR-20a.
In the present study, we employed an established animal model
of pulmonary hypertension and found that (i) i.p. injection of antag-
omiR in general is a feasible approach to efficiently down-regulate
distinct miRNAs in target tissues; (ii) antagonization of miR-20a
reduces the hypoxia-induced remodelling of pulmonary arterioles
Figure 5 Proliferation is reduced upon transfection with antagomiR-20a. (A) The BrdU assay performed in human pulmonary arterial smooth
muscle cells after transfection of antagomiR-20a and antagomiR_MM showed significant inhibition of cell growth as measured by absorbance at
450 nm. Conversely, transfection of pre-miRs increased proliferation significantly. (B) p21 was found to be up-regulated in
antagomiR-20a-transfected human pulmonary arterial smooth muscle cells as indicated by western Blot (at 24 h of antagomiR-20a transfection).
(C) mRNA levels of p21 were found to be increased in human pulmonary arterial smooth muscle cells when miR-20a expression was blocked as
assessed by qPCR. (D) Proof of principle. miR-20a levels were found to be reduced upon transfection with antagomiR-20a.
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and, subsequently, reduces right heart hypertrophy in hypoxic
animals; and, (iii) that treatment with antagomiR-20a restores
functional expression levels of BMPR2 both in vivo and in vitro.
In these experiments, antagonization of miR-20a significantly
reduced the vascular remodelling in hypoxic animals as assessed
by wall thickness and luminal occlusion of small pulmonary arteries.
Thickness of the vessel wall was less prominent than in hypoxic
control animals, probably due to a lesser grade of muscularization
upon reduced proliferation of vascular smooth muscle cells in the
medial layer. The vascular occlusion of these vessels that is com-
monly observed in pulmonary hypertension and might result
from vasoconstriction, proliferation of the intimal and medial
layer and the development of plexiform lesions, has also been
found to be reduced significantly in antagomiR-20a-treated
animals. Vascular occlusion and narrowing of the pulmonary arter-
ial lumen increase pulmonary vascular resistance and right ven-
tricular afterload; these alterations result in cardiac hypertrophy
and, ultimately, right heart failure. In our experiments, antagomiR-
20a-treated animals revealed significantly less right ventricular
hypertrophy than their mock-treated hypoxic controls, indicating
improved pulmonary arterial haemodynamics in antagomiR-
20a-treated mice. However, since the expression of miR-20a has
been antagonized not only in the lungs, it remains unclear
whether the observed reduction in right ventricular hypertrophy
is an indirect effect of reduced pulmonary arterial pressure or,
alternatively, whether it might be due to concomitant inhibition
of miR-20a in cardiac myocytes. In contrast to other miRNAs,
including miR-133,18 miR-21,19 or miR-27b20 that also have been
antagonized experimentally, miR-20a has not been described to
be overexpressed in response to cardiac stress. With regard to
other cell types, treatment with antagomiR-20a did not significantly
alter the hypoxia-induced polycythaemia of erythrocytes, indicating
that, at least, no such pleiotropic effects by antagonizing miR-20a
have occurred on haematopoietic cells.
We further showed that treatment with antagomiR-20a
increased the expression levels of BMPR2 in lung tissue, thus con-
firming that miR-20a targets the mRNA of BMPR2 as it was already
suggested previously by our in vitro data on human pulmonary ar-
terial endothelial cells. Moreover, in the current study transfection
of smooth muscle cells with antagomiR-20a could rescue expres-
sion and downstream signalling events of BMPR2 that was silenced
by siRNA (Supplementary material online, Figure S7). It has been
discussed controversially, whether the observed dysregulation of
BMPR2 in several forms of pulmonary hypertension might be of
pathogenetic relevance. However, genetic studies and recent in
vitro data suggest that BMPR2 and its downstream signalling play
an important role in cell proliferation, vascular remodelling and,
thus, in the development of pulmonary hypertension. For instance,
Wong et al.21 showed that the activation of the BMPR2 signalling
pathway in HPASMCs leads to the inhibition of proliferation prob-
ably due to the induction of the cell cycle repressor p21. Our find-
ings are along the line of these data and further provide evidence
both in vivo and in vitro that a functional BMPR2 signalling prevents
major vascular remodelling within small pulmonary arteries. In par-
ticular, we showed that the restoration of BMPR2 expression in
lung tissue leads to activation of the BMP-2 target Id-2. Similarly,
in vitro, stimulation of HPASMCs with BMP-2 and transfection
with antagomiR-20a revealed increased BMP-2 signalling as indi-
cated by enhanced promoter activity of Id-1 and up-regulated ex-
pression levels of Id-1 and -2. These transcription factors have
been associated with cell proliferation;22 activated Id-1/-2 thus
would reduce the proliferation rate of cells. Here, levels of Id-1
and -2 have been found to be increased in antagomiR-20a-treated
HPASMCs, and, in subsequent experiments, the proliferation of
HPASMCs was reduced by transfection of antagomiR-20a,
whereas apoptosis was not affected significantly. These data
strongly indicate that the restoration of BMPR2 by treatment
with antagomiR-20a is functional and, thus, reconstitutes the
downstream signalling of BMPR2 in pulmonary arterial smooth
muscle cells and in lung tissue. The reduced proliferation of
smooth muscle cells was further shown to be associated with
enhanced expression of the cell cycle repressor p21. We suggest
that the observed increased expression of p21 by antagomiR-20a
is caused by two ally acting mechanisms. On the one hand it was
shown that miR-20a directly regulates the expression of p21,23
and on the other hand Wong et al.21 demonstrated that BMP-2 sig-
nalling enhances protein levels of p21. Therefore, antagomiR-20a
treatment increases p21 levels by the inhibition of miR-20a and
by enhancing BMP-2 signalling, which might result in growth
arrest of smooth muscle cells. In summary, functional restoration
of BMPR2 appears to inhibit the development of hypoxia-induced
vascular remodelling by enhanced intracellular signalling activity
and reduced proliferation.
Finally, antagonization of miR-20a, one of the key microRNAs in
pulmonary hypertension, was successfully achieved in hypoxic mice
by repeated i.p. injections. Since antagomiRs are employed to a
growing extent for antagonization of distinct microRNAs for
pathogenetic investigations and therapeutic purposes,11 these find-
ings make antagomiRs to interesting tools for several reasons:
down-regulation of miR-20a was observed in target organs
behind the liver, a finding that mutually excludes a significant
hepatic first-pass effect; the effects have been longstanding, thus
minimizing the need for frequent applications; toxic effects have
not been observed in terms of well-being of the animals or
interferon-gamma expression in liver tissue (data not shown).
Moreover, to our knowledge, this is the first report on i.p. applica-
tion of antagomiRs.
Our data might be limited by the fact that the increase in
miR-20a observed under hypoxic conditions did not reach statistic-
al significance. However, miRs are considered to act as fine tuners
of gene regulation, and, thus, even small and non-significant eleva-
tions might have functional relevance. Accordingly, the increase of
miR-20a and other members of the cluster miR-17/92 was rather
small in other in vivo studies performed in experimental models of
pulmonary hypertension.13 Together with these data, the experi-
ments from our study underscore the major importance of a com-
pletely intact BMPR2 signalling pathway to prevent vascular
remodelling; here, this could be achieved by specific inhibition of
miR-20a, an endogenously expressed repressor of BMPR2, result-
ing in normalization of BMPR2 mRNA levels or overexpression of
protein levels, respectively.
Taken together, we show here for the first time that the devel-
opment of hypoxia-induced changes of small pulmonary arteries
can be prevented by the application of antagomiR-20a, though it
M. Brock et al.3210
remains speculative whether this treatment would also reverse the
once established disease. Our in vivo data, however, suggest that
antagonization of miR-20a inhibits vascular remodelling of pulmon-
ary arteries in patients with pulmonary hypertension and, thus,
might provide a major impact on our understanding and treatment
of this disease.
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Supplementary material is available at European Heart Journal
online.
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